Martin Borch Jensen

Martin Borch Jensen has articulated and acted around a longevity-oriented vision through mitochondrial aging research, a therapeutics company targeting age-related diseases, and Norn Group's grantmaking, talent development, and roadmapping. However, the evidence here does not include a clear destination quote, explicit theory of aging, public timeline, or concrete end-state vision for ending aging or materially extending healthy lifespan, so the score is moderate rather than high.

Scientific impact is applicable and supported by primary citation metrics. The OpenAlex profile shows a credible but not field-defining research record: h-index 16, 1,955 total citations across 76 works, with top-cited papers in the low hundreds. Several works are directly relevant to aging biology, mitochondrial proteostasis, NAD+/mitophagy, and accelerated aging syndromes, indicating real technical contribution, but the citation weight is moderate rather than agenda-setting at the field level.

There is limited evidence of longevity-directed institution building through founding and leading Norn Group, described as a nonprofit involved in grantmaking, talent development, and roadmapping. However, the evidence provides no disclosed capital amounts, no specific grants or investments, and no corroborated record of personal capital deployment or fund allocation. This supports a low score rather than N/A.

The dimension applies because Jensen has founder/operator activity in longevity, but the provided evidence contains almost no direct strategy signal. Founding Gordian Biotechnology and Norn Group suggests some longevity-field deployment, yet the evidence does not establish an early, contrarian, thesis-coherent, or counterfactually important bet, nor a clear rationale behind those choices.

The dimension applies: the evidence says Jensen founded or co-founded multiple longevity-relevant organizations, including Gordian Biotechnology and Norn Group. That is a meaningful field-creation signal, especially because active organizations can make longevity work more legible and operational for others. However, the provided independent source only corroborates Jensen's Gordian Biotechnology affiliation in the aging-research ecosystem, not the founding claim or broader field-building impact, so the independence gate prevents a score above 5.

The dimension applies, but the provided evidence contains almost no direct support for public risk-taking, career sacrifice, contrarian advocacy, sustained conviction under criticism, magnitude-relative bet, or self-experimentation. The available facts show Martin Borch Jensen as a longevity scientist-operator and nonprofit founder, which suggests commitment to the field, but not bravery or conviction in the rubric's required sense.

The multiplier_effect dimension applies because the evidence shows Martin Borch Jensen founded or co-founded multiple organizations, including Norn Group and Gordian Biotechnology, which suggests some leverage beyond direct research. However, the provided evidence does not show independently corroborated downstream effects such as attracting major capital, talent networks, policy attention, founder lineage, public legitimacy, or follow-on projects. Bibliometrics indicate a credible scientific footprint, but they mostly support scientific impact rather than multiplier effects.